ORIGINAL ARTICLE

A comparative study of continuous positive airway pressure (CPAP) and intermittent positive pressure ventilation (IPPV) in patients with flail chest

M Gunduz, H Unlugenc, M Ozalevli, K Inanoglu, H Akman

Emerg Med J 2005;22:325–329. doi: 10.1136/emj.2004.019786

See end of article for authors' affiliations

Correspondence to:
Dr M Gunduz, Çukurova
University Faculty of
Medicine, Department of
Anaesthesiology, 01330,
Balcali, Adana, Turkey;
hmurat@cu.edu.tr

Accepted
14 November 2004

Introduction: The role of non-invasive positive pressure ventilation delivered through a face mask in patients with flail chest is uncertain. We conducted a prospective, randomised study of continuous positive airway pressure (CPAP) given via a face mask to spontaneously breathing patients compared with intermittent positive pressure ventilation (IPPV) with endotracheal intubation (ETI) in 52 patients with flail chest who required mechanical ventilation.

Method: The 52 mechanically ventilated patients were randomly divided into two treatment groups: the ET group (n=27) received mechanical ventilation with ETI, whereas patients in the CPAP group (n=25) received CPAP via a face mask with patient controlled analgesia (PCA). Major complications, arterial blood gas levels, length of intensive care unit (ICU) stay and ICU survival rate were recorded.

Results: Nosocomial infection was diagnosed in 10 of 21 patients in the ET group, but only in 4 of 22 in the CPAP group (p=0.001). Mean PO₂ was significantly higher in the ET group in the first 2 days (p<0.05). There were no significant differences in length of ICU stay between groups. Twenty CPAP patients survived, but only 14 of 21 intubated patients who received IPPV (p<0.01).

Conclusion: Non-invasive CPAP with PCA led to lower mortality and a lower nosocomial infection rate, but similar oxygenation and length of ICU stay. The study supports the application of CPAP at least as a first line of treatment for flail chest caused by blunt thoracic trauma.

Patients with flail chest often require critical care for analgesia and ventilation. Mechanical ventilation has been used for more than 40 years,¹ but prolonged ventilation increases the incidence of complications such as ventilator induced lung injury, major atelectasis, and hospital acquired pneumonia. The latter has a poor prognosis, especially in patients with flail chest injury.^{2–4}

Trinkle *et al* proposed the use of epidural analgesia and adequate oxygenation;⁵ however, non-invasive positive pressure ventilation has recently been proposed. For patients with chest wall trauma who remain hypoxic despite adequate regional analgesia and high flow oxygen, continuous positive airway pressure (CPAP) may improve oxygenation and avoid endotracheal intubation.⁶

Pain from rib fracture may affect pulmonary function, morbidity, and length of intensive care unit stay. Therefore, effective pain management is a crucial part of therapy for rib fractures by allowing adequate inspiration and clearance of secretions. Previous trials have varied from epidural techniques to patient controlled analgesia (PCA) techniques and have used several outcome variables. However, no significant difference in the lengths of intensive care unit or hospital stays or the incidence of pulmonary complications or organ failure has been reported between epidural and PCA techniques.^{7–8}

In this prospective, randomised study we measured the complications, mortality, oxygenation, and length of intensive care unit (ICU) stay of spontaneously breathing patients with flail chest who required mechanical ventilation given CPAP via a face mask compared with patients given intermittent positive pressure ventilation (IPPV) with endotracheal intubation (ETI).

MATERIALS AND METHODS

The ethics committee of the Faculty of Medicine of Çukurova University approved the study protocol, and each patient or

their next of kin gave informed consent. In total, 52 patients, between the ages of 23 and 49 years, were admitted to our hospital with thoracic trauma between 1 January 2000, and 1 April 2004. Computed lung tomography (CLT) and plain chest x rays were taken routinely on admission, to evaluate patients with multiple traumas. Patients included in the study demonstrated: (a) five or more rib fractures in a row, or three or more segmental (two fractures in one rib) rib fractures on plain chest x ray or CLT and confirmed by the presence of a flail segment—that is, paradoxical motion of the chest wall; (b) acute respiratory distress and severe dyspnoea with respiratory rate (RR) >25/min; (c) peripheral oxygen saturation (SpO₂) <90% while breathing 10 l/min oxygen in the emergency room; and (d) a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO₂/FiO₂) ≤300 while receiving FiO₂ ≥0.5 in the ICU.

As mortality is associated with the degree and extent of accompanying injuries,⁹ all patients with flail chest were also assessed using the 25 point Thoracic Trauma Severity Score (TTSS) during the first 2 hours of admission (table 1).¹⁰ Patients were excluded from the study on the following grounds: requiring ETI immediately on admission due to severe respiratory distress, haemodynamic instability, encephalopathy, respiratory failure caused by neurological disease or asthma attack; emergency surgery following admission; non-cooperative patients unable to use the face mask; coma or confusion; inability to protect the airway; severe acidosis,

Abbreviations: CLT, computed lung tomography; CPAP, continuous positive airway pressure; ETI, endotracheal intubation; ETMV, endotracheal intubation and mechanical ventilation; ICU, intensive care unit; IPPV, intermittent positive pressure ventilation; NPPV, non-invasive positive pressure ventilation; PCA, patient controlled analgesia; PEEP, positive end expiratory pressure; RR, respiratory rate; TTSS, Thoracic Trauma Severity Score

Table 1 Thoracic trauma severity score

Grade	PaO ₂ /FiO ₂	Rib fracture	Contusion	Pleural involvement	Age	Points
0	>400	0	None	None	<30	0
I	300–400	1–3	1 lobe, unilateral	PT	30–41	1
II	200–300	3–6	1 lobe bilateral or 2 lobes unilateral	HT/HPT unilateral	42–54	2
III	150–200	>3 bilateral	<2 lobes bilateral	HT/HPT bilateral	55–70	3
IV	<150	Flail chest	<2 lobes bilateral	TPT	>70	5

PT, pneumothorax; HT, haemothorax; HPT, haemopneumothorax; TPT, tension pneumothorax. For calculation of the total score, all categories were summed. A minimum value of 0 points and a maximum value of 25 points can be achieved.

significant co-morbidity; vomiting; obstructed bowel; or haemodynamic instability.

Of the 52 patients, 43 (83%), having a TTSS between 5 and 15 were consecutively randomised to one of two ventilation treatment groups: the ET group ($n = 21$) received mechanical ventilation with ETI, and the CPAP group ($n = 22$) received CPAP via a face mask. The protocol allowed for CPAP patients to be intubated if symptoms or signs of respiratory distress continued or progressed (respiratory rate (RR) >25 l/min; SpO₂ <90% while breathing 10 l/min oxygen and PaO₂/FiO₂ ≤200 while receiving FiO₂ = 1.

Mechanical ventilation

Following ETI, IPPV with positive end expiratory pressure (PEEP) (50–100 mmH₂O) was controlled with a tidal volume of 6–10 ml/kg, RR 10 l/min, to produce an end tidal carbon dioxide partial pressure in the range of 4.2–5 kPa; hypercapnia was not allowed. Peak inspiratory pressure was limited to 200–300 mmH₂O. End expiratory pressure was increased in increments of 20–30 mmH₂O up to 100 mmH₂O, until the required FiO₂ was ≤0.6. Mechanical ventilation was administered with a Drager Evita 4 ventilator.

Following improvement in the clinical condition and blood gas and the ventilatory parameters (RR, SpO₂, gas exchange values), when spontaneous breathing reappeared, ventilator settings were changed to intermittent mandatory ventilation (rate 4–7 breaths/min) for weaning from mechanical ventilation. Pressure support (140 to 200 mmH₂O), was adjusted to achieve a spontaneous tidal volume of 8 to 10 ml/kg/min and a respiratory rate of <25 breaths/min, with accessory muscle activity absent. All patients were weaned from the ventilator by reducing the level of pressure support by 40 mmH₂O twice and then decreasing the ventilatory rate by two breaths/min at 2 hour intervals, as tolerated. Patients who tolerated an intermittent mandatory ventilation rate of 0.5 breaths/min, a pressure support level of 80 mmH₂O, and an FiO₂ of ≤0.5 then underwent a 2 hour T piece trial, followed by extubation if respiratory rate remained <25 breaths/min and PaO₂ >75 mm Hg.

As the clinical condition and blood gas and the ventilatory parameters (RR, SpO₂, gas exchange values) improved, ventilation support was tapered off by progressively reducing the number of daily trials, or was stopped if the improvement remained stable (SpO₂ >90%, RR <25 breaths/min).

Continuous positive pressure ventilation

Patients in the CPAP group were instructed in the use of the facemask, through which CPAP was delivered by a Drager Evita 4 ventilator. CPAP was increased in increments of 20–30 mmH₂O repeatedly up to 80–150 mmH₂O until the FiO₂ requirement was ≤0.6. The CPAP level was adjusted on the basis of continuous oximetry and measurements of arterial blood gases.

CPAP was stopped if the respiratory rate was <25 breaths/min, PaO₂ >75 mm Hg with a FiO₂ of 0.5, without ventilatory support, and if PaO₂:FiO₂ exceeded 200 for 24 hours. Therapy was considered successful if intubation was avoided and the patient could be transferred out of the ICU. Patients received CPAP for at least 6 hours each day, depending on their ability to tolerate it. Each day, however, patients were allowed to breathe spontaneously, with oxygen but without assistance, for 2 hours. The overall duration of CPAP ventilation was determined on the basis of clinical criteria and arterial blood gas levels; in each case, the decision was made by the physician in charge.

Monitoring

Monitoring of patients in the ICU included lead II electrocardiogram, pulse oximetry, invasive blood pressure, central venous pressure, end tidal CO₂ pressure, core temperature, urine output, and ventilator settings (including tidal volume, respiratory rate, lung compliance, airway resistance, peak inspiratory pressure). Ventilator settings were adjusted on the basis of continuous pulse oximetry and measurements of arterial blood gases.

Sedation and analgesia

In the ET group patients, ETI was facilitated by an intravenous bolus of vecuronium (0.1–0.2 mg/kg). A propofol (2–3 mg/kg/h) plus fentanyl (0.002 µg/kg/min) combination was infused continuously. Thereafter no neuromuscular blocking agent was used.

In the CPAP group, patients were sedated with an intravenous midazolam infusion (0.015 mg/kg/h) and received morphine sulphate patient controlled analgesia. When the patient was breathing spontaneously on admission, and stable vital signs and breathing were maintained under oxygen therapy, a standardised (0.05 mg/kg) loading dose of morphine was given. Patients were then allowed to use bolus doses of morphine (0.0125 mg/kg every 30 minutes without time limit) with a PCA device (Abbott Pain Management Provider, class II, type CF; Abbott, Chicago, IL, USA). Verbal rating scores were measured at 6 hour intervals for 7 days and recorded daily as means (SD), and morphine consumption was recorded daily for 7 days in the CPAP group. Additionally, ondansetron 4 mg intravenously was prescribed every 12 hours on request as the rescue anti-emetic therapy. In all patients, chest physiotherapy (percussion and vibration) was initiated following pain control.

Measurements

All patients with flail chest were assessed on admission using the APACHE III scoring system, and daily thereafter. TTSS and blood count were obtained at the start of the study and chest x rays daily.¹⁰ Patients were monitored for the development of infections or other complications. Those

developing manifestations of pneumonia, including radiographic evidence of persistent pulmonary infiltrates, hyperthermia or hypothermia, purulent tracheobronchial secretions, a high white cell count, and worsening of pulmonary gas exchange, underwent bronchoscopy with bronchoalveolar lavage. Pneumonia was diagnosed when at least 100 000 colony forming units of bacteria/ml were measured in bronchoalveolar lavage fluids.

TTSS was calculated according to Pape and Remmers.¹⁰ Arterial blood gas levels were determined at baseline and at 2 h intervals thereafter for 7 days. Finally, length of ICU stay, ICU survival rate, and the development of major complications associated with IPPV (pneumothorax, nosocomial infections assessed by positive blood culture) or CPAP (pneumothorax, gastric distension) were also recorded.

End points

In this study, the primary end point was the ICU mortality. Secondary end points included complications associated with IPPV or CPAP as above, oxygenation, and length of ICU stay.

Statistical analysis

Statistical analyses were performed using the statistical package SPSS (version 10.0; SPSS, Chicago, IL, USA). Results are given as means (SD). Demographic and physiological characteristics of the two groups were compared with Student's *t* test. Categorical data were analysed by using the χ^2 test. Statistical significance was set at $p < 0.05$.

RESULTS

Of the original 52 patients, nine were excluded from the study: seven required emergency endotracheal intubation because of severe respiratory distress (RR > 25 breaths/min, SpO₂ $< 90\%$ while breathing 10 l/min oxygen, and PaO₂/FiO₂ ≤ 200 while receiving an FiO₂ ≥ 1), and deterioration in neurological status (Glasgow Coma Scale score of 8 or less) immediately after admission to the intensive care unit, while the other two patients were haemodynamically unstable. The remaining 43 patients were enrolled ($n = 21$ in the ET group and $n = 22$ in the CPAP group) in this study.

There were no differences in age, sex, and weight between the two groups. APACHE III scores were similar between two groups on admission. Clinical and physiological characteristics on admission to the ICU are shown in table 2. In the first two days, PO₂ was significantly greater in the ET group ($p < 0.05$), but this reduced after 2 days to similar levels to the CPAP group (fig 1). There were no differences in PCO₂ between the two groups.

The sedated but conscious CPAP patients experienced some difficulties in adapting to delivery via the face mask for the first 2 days, but thereafter tolerated the treatment well. No patient in this group needed any change in ventilator setting or required intubation. The mean (SD) CPAP level was 100 (20) mmH₂O, and duration of CPAP application was 15 (4) days. Verbal rating scores and morphine consumptions decreased with time in the CPAP group (table 3).

Mean ICU stay was slightly but not significantly longer in the ET group. Mean hospital stay did not differ significantly between groups (16 (3) v 15 (4) days). Nosocomial infection developed in 10 patients in the ET group: nosocomial pneumonia (streptococcal pneumonia $n = 2$, *Staphylococcus aureus* $n = 5$, and *Klebsiella* pneumonia $n = 3$), and in four patients in the CPAP group: nosocomial pneumonia (streptococcal pneumonia $n = 2$), urinary infection (*Escherichia coli* $n = 2$). Seven patients in the ET group and two patients in the CPAP group died from nosocomial infection and related complications. Complications related with death are summarised in table 4. No other complications associated with IPPV (barotrauma) or CPAP (pneumothorax, gastric

Table 2 Clinical and physiological characteristics on admission to the intensive care unit

Variable	ET group (n = 21)	CPAP group (n = 22)
Sex (F/M)	7/14	9/13
Age (years)	38 (10)	40 (9)
APACHE III	30 (5)	32 (7)
Weight (kg)	71 (5)	70 (3)
pO ₂ (mmHg)	78 (15)	106 (40)
pCO ₂ (mmHg)	39 (3)	32 (6)
paO ₂ /FiO ₂	200 (50)	190 (40)
Length of ICU stay (day)	16 (3)	15 (4)
Chest wall injuries (n)(%)		
2–3 ribs	8 (38%)	7 (31.8%)
> 3 ribs	13 (62%)	15 (68.2%)
HT	4 (19%)	6 (27.3%)
PT	9 (42.8%)	11 (50%)
HPT	3 (14.2%)	2 (9.1%)
TPT	1 (4.76%)	0 (%)

HT, Haemothorax; PT, pneumothorax; HPT, haemopneumothorax; TPT, tension pneumothorax. Data are shown as mean (SD).

Figure 1 The PO₂ in both groups during treatment. In the first two days, PO₂ was significantly greater in the ET group (diamonds) ($p < 0.05$), but this reduced after 2 days, to similar levels to the CPAP group (squares). There were no differences in PCO₂ between the two groups.

Table 3 Verbal rating score and morphine consumption in the CPAP group

Day	VRS		Morphine consumption (mg)	
	Mean (SD)	Median (min-max)	Mean (SD)	Median (min-max)
1	6.0 (0.53)	6 (5–7)	35.40 (1.40)	36 (30–36)
2	5.36 (0.072)	5 (4–7)	31.86 (2.62)	32 (24–36)
3	4.72 (0.88)	4.5 (4–7)	27.72 (3.02)	28 (20–30)
4	3.95 (0.65)	4 (3–5)	19.72 (4.37)	18.5 (14–28)
5	3.18 (0.50)	3 (2–4)	15.81 (3.38)	15.5 (12–26)
6	2.68 (0.56)	3 (2–4)	13.77 (2.15)	13.5 (12–20)
7	2.13 (0.46)	2 (2–4)	12.40 (0.95)	12 (12–16)

distension) were recorded. Clearly, patients receiving CPAP had a better survival ($p < 0.01$).

DISCUSSION

This is the first study to evaluate use of CPAP for the treatment of flail chest caused by blunt thoracic trauma. Many other therapeutic approaches, including surgical, have been previously reported. In the past, especially in cases of severe lung contusion and prolonged mechanical ventilation, surgery has been recommended for external stabilisation of the chest wall.^{11–13} The first modern approach to flail chest

Table 4 Complications related to death

Complication	ET group (n = 21) (n) (%)	CPAP group (n = 22) (n) (%)
Pneumonia	10 (47.6%)	2 (9.1%)
Urinary infection	0 (0%)	2 (9.1%)
Sepsis	5 (23.8%)	2 (9.1%)
Renal failure	4 (19.1%)	1 (4.5%)
MOF	1 (4.8%)	0 (0%)
ARDS	1 (4.8%)	0 (0%)

MOF, multiple organ failure; ARDS, acute respiratory distress syndrome.

was that of Avery *et al*, who reported that continued mechanical ventilation was required to achieve the internal stabilisation of the chest wall.¹⁴ Cullen *et al* recommended IMV for stabilisation in the treatment of flail chest injury.¹⁵ Antonelli *et al*, however, reported that the mechanical ventilation procedure should be more selective and showed that application of the two different ventilatory techniques (invasive with non-invasive ventilatory treatment) in hypoxaemic respiratory failure resulted in similar short term improvements in arterial blood gases, while non-invasive mechanical ventilation was associated with fewer serious complications and a shorter stay in the ICU compared with conventional mechanical ventilation.¹⁶

The effectiveness of non-invasive positive pressure ventilation (NPPV) in decreasing mortality and endotracheal intubation rates in patients with hypoxaemic respiratory failure has been demonstrated in meta-analyses,¹⁷ while the data to support the use of NPPV in these patients with hypoxaemic respiratory failure is inconclusive at present. Several prospective randomised trials have demonstrated that non-invasive ventilation reduces both the need for ETI and the complication rate, and also shortens the length of ICU stay, and improves survival in patients with chronic obstructive pulmonary disease.^{18–19} A recent study evaluated whether facemask CPAP is physiologically beneficial, and reduces the need for endotracheal intubation and mechanical ventilation (ETMV) in patients with acute lung injury.²⁰ Despite an early favourable physiological response to CPAP in terms of comfort and oxygenation, there were no differences in the need for ETMV, in hospital mortality, or length of ICU stay. However, in a retrospective study, Tanaka *et al* reported that CPAP with pressure support during spontaneous breathing reduced both complications and the duration of mechanical ventilation.²¹ One randomised controlled trial²² and two case series^{23–24} support the use of CPAP in isolated chest trauma. The trial was performed on 69 patients with more than two rib fractures and hypoxaemia.²² CPAP and regional analgesia were compared with immediate intubation followed by IPPV with PEEP. CPAP resulted in fewer treatment days (mean 4.5 v 7.3), fewer mean ICU days (5.3 v 9.5), and hospital days (8.4 v 14.6). Kasai *et al*²⁴ also showed that mechanical ventilation led to longer intensive care compared to conservative approaches. In our study, there were no differences between durations of ICU stay between groups, but possibly a greater number of patients would have shown a difference.

Tzelepis *et al* investigated chest wall distortion in patients with flail chest injury using three different ventilator modes: continuous mandatory ventilation, intermittent mandatory ventilation, and CPAP.²⁵ Chest wall distortion was less during spontaneous breathing with CPAP than during intermittent mandatory ventilation. CPAP using a high gas flow system of 80–100 l/min resulted in the least distortion, possibly related to the positive pleural pressure and minimal load of the high gas flow system. This suggests that CPAP provides more effective stabilisation in flail chest injury than any other

positive pressure ventilation. These findings might also be true for CPAP delivered via face mask.

Ventilator related pneumonia, sepsis, septic shock, and other complications have an important effect on mortality in patients with chest trauma and developed flail chest.^{26–28} Pneumonia is the commonest infection in patients with flail chest injury, and bronchial hygiene is an important factor in its prevention. Maintenance of bronchial hygiene is difficult in intubated patients. The lower nosocomial infection rate in the CPAP group suggests that spontaneous breathing with CPAP permits better bronchial hygiene. Respiratory physiotherapy is also useful for bronchial hygiene; in our study, it was initiated following pain control. A lack of adequate bronchial hygiene undoubtedly contributes to pulmonary morbidity.²¹

Pneumothorax is another cause of pulmonary morbidity. It might be suggested that IPPV is more likely to result in barotrauma,²² but when CPAP is used in patients with rib fractures, the risk of pneumothorax is similar.⁶ However, only one report describes a case of pneumothorax with CPAP delivered via mask.²⁷ There was no overt barotrauma in the present study.

Bauer *et al*²⁹ reported that mechanical ventilation of more than 48 hours' duration is the most important risk factor for ventilator related pneumonias. Our pneumonia rate in the ET group was 48% (n = 10), but only 9% (n = 2) in the CPAP group (p < 0.001), which is probably related to the lower nosocomial infection rate with CPAP. These findings agree with those of uncontrolled studies using CPAP or IPPV;^{22–24–30} however, in a multiple logistic regression model, failure to improve with mask CPAP was an independent predictor of death.³¹

CPAP was less effective in improving PO₂ in the first 2 days than IPPV, possibly because of difficulty in adaptation to the CPAP mask. Thereafter, PO₂ levels in the CPAP and IPPV groups were similar. Poor oxygenation in patients receiving CPAP is thought to be related to severe pain, analgesia being an important part of the treatment of flail chest. However, as it was difficult for patients with flail chest injury on admission to assume the lateral position for regional analgesic techniques, PCA is an acceptable alternative.

In conclusion, non-invasive CPAP with PCA led to lower mortality and nosocomial infection rate. Oxygenation and length of ICU stay were similar. The findings suggest that CPAP should be tried as a first step in the treatment of flail chest caused by blunt thoracic trauma. Further studies and larger groups are needed to draw firm conclusions and to establish the importance of this protocol in the treatment of flail chest injury.

Authors' affiliations

M Gunduz, M Ozalevli, H Unlugenc, K Inanoglu, H Akman, Çukurova University Faculty of Medicine Department of Anaesthesiology Balcali, Adana, Turkey;

Competing interests: none declared

REFERENCES

- Rodriguez A. Injuries of chest wall, the lung and the pleura. In: Turney SZ, Rodriguez A, Cowley RA, eds. *Management of cardiothoracic trauma*, edn. Baltimore: Williams and Wilkins, 1990:155–77.
- Paris F, Terrazona V, Garcia-Zarza A. Controversial aspects of surgical fixation for traumatic flail chest. In: *International trends of general thoracic surgery*. Surgical management of chest injuries. Saunders, Philadelphia, 1991:306–9.
- Cross AS, Roupe B. Role of respiratory assistance device in endemic nosocomial pneumonia. *Am J Med* 1981;**70**:681–5.
- DE Lanches LM, Kilinsky VK. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. *Am Rev Respir Dis* 1986;**133**:792–6.
- Trinkle JK, Richardson JD, Frenz JL, *et al*. Management of flail chest without mechanical ventilation. *Ann Thoracic Surg* 1975;**19**:355–63.

- 6 **Boundain S**, Blumenthal S, Cooper B, *et al* (British Thoracic Society Standards of Care Committee). Non-invasive ventilation in acute respiratory failure. *Thorax* 2002;**57**:192–211.
- 7 **Wu CL**, Jani ND, Perkins FM, *et al*. Thoracic epidural versus intravenous patient-controlled analgesia for the treatment of rib fracture pain after motor vehicle crash. *J Trauma* 1999;**47**:564–7.
- 8 **Moon MR**, Luchette FA, Gibson SW. Prospective randomized comparison of epidural versus parenteral opioid analgesia in thoracic trauma. *Ann Surg* 1999;**229**:684–91.
- 9 **Ciraulo LL**, Elliot D, Mitchell KA, *et al*. Flail chest as a marker for significant injuries. *J Am Coll Surg* 1994;**178**:466–70.
- 10 **Pape HC**, Remmes D, Rice J. Appraisal of early evaluation of blunt chest trauma: Development of a standardized scoring system for initial clinical decision making. *J Trauma* 2000;**49**:496–504.
- 11 **Thomas AN**, Blaisdell FW, Lewis FR Jr, *et al*. Operative stabilization for flail chest after blunt trauma. *J Thorac Cardiovasc Surg* 1978;**75**:793–801.
- 12 **Freedland M**, Wilson RF, Bender JS, *et al*. The management of flail chest injury, factors affecting outcome. *J Trauma* 1990;**30**:1460–8.
- 13 **Trunkey DD**. Chest wall injuries. In: *Trauma management: cervicothoracic trauma*, 2nd ed. In: Blaisdell FW, Trunkey DD, eds. New York: Thieme, 1994:355–73.
- 14 **Avery EE**, Morch ET, Benson DW. Critically crushed chests: A new method of treatment with continuous mechanical hyperventilation to produce alkalotic apnea and internal pneumatic stabilization. *J Thorac Surg* 1956;**32**:291–311.
- 15 **Cullen P**, Modell JH, Dirby RR. Treatment of flail chest. Use of intermittent mandatory ventilation and positive end-expiratory pressure. *Arch Surg* 1975;**110**:1099–103.
- 16 **Antonelli M**, Conti G, Rocco M, *et al*. A comparison of noninvasive positive pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998;**339**:429–35.
- 17 **Peter JV**, Moran JL, Phillips-Hughes J, *et al*. Noninvasive ventilation in acute respiratory failure—A meta-analysis update. *Crit Care Med* 2002;**30**:555–62.
- 18 **Wysocki M**, Tric L, Wolff MA, *et al*. Noninvasive pressure support ventilation in patients with acute respiratory failure. *Chest* 1993;**103**:907–13.
- 19 **Keenan SP**, Kernerman PD, Cook DJ, *et al*. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta analysis. *Crit Care Med* 1997;**25**:1685–92.
- 20 **Golberg P**, Reissmann H, Maltais F, *et al*. Efficacy of noninvasive CPAP in COPD with acute respiratory failure. *Eur Respir J* 1995;**8**:1894–900.
- 21 **Tanaka H**, Tajimi K, Endoh Y, *et al*. Pneumatic stabilization for flail chest injury: an 11 year study. *Surg Today* 2001;**31**:12–17.
- 22 **Bolliger CT**, Van Eeden SF. Treatment of multi rib fractures. Randomized controlled trial comparing ventilatory with nonventilatory management. *Chest* 1990;**97**:943–8.
- 23 **Hurst JM**, DeHaven CB, Branson RD. Use of CPAP mask as the sole mode of ventilatory support in trauma patients with mild to moderate respiratory insufficiency. *J Trauma* 1985;**25**:1065–8.
- 24 **Linton DM**, Potgieter PD. Conservative management of blunt chest trauma. *S Afr Med J* 1982;**61**:917–19.
- 25 **Tzelepis GE**, McCool FD, Hoppin FG. Chest wall distortion with flail chest. *Am Rev Respir Dis* 1989;**140**:31–7.
- 26 **Kingston DW**, Phang PT, Leathley MJ. Increased incidence of nosocomial pneumonia in mechanically ventilated patient with subclinical aspiration. *Am J Surg* 1991;**161**:589–92.
- 27 **Craven DE**, Steger KA. Epidemiology of nosocomial pneumonia. New perspectives on an old disease. *Chest* 1995;**108**(suppl2):1–16S.
- 28 **Gregg RW**, Friedman BC, Williams JF, *et al*. Continuous positive airway pressure by face mask in *Pneumocystis Carinii* pneumonia. *Crit Care Med* 1990;**18**:21–4.
- 29 **Bauer TT**, Ferrer R, Angrill J, *et al*. Ventilator associated pneumonia: incidence, risk factors and microbiology. *Semin Respir Infect* 2000;**15**:272–9.
- 30 **Confalonieri M**, Calderini E, Terraciano S, *et al*. Noninvasive ventilation for treating acute respiratory failure in AIDS patients with *pneumocystis carinii* pneumonia. *Intensive Care Med* 2002;**28**:1233–8.
- 31 **Bedos JP**, Dumoulin JL, Gachot B, *et al*. *Pneumocystis carinii* pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus. *Crit Care Med* 1999;**27**:1109–15.